News

Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH), a post-hoc analysis of the Phase 3 GRIPHON trial shows. The study, “Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III…

Despite having better heart function and less severe disease, patients with a lung disease underlying their pulmonary hypertension (PH) have survival rates that are as poor as those with idiopathic PH, a study suggests. The study, “Outcomes of Lung Disease-Associated Pulmonary Hypertension and Impact of Elevated Pulmonary Vascular Resistance,”…

The heart’s ventricular mass may be an early prognostic biomarker for predicting the risk of heart failure and death in people with pulmonary arterial hypertension (PAH), a recent study suggests. The research, “Ventricular mass…

As they have for the past five years, members of the pulmonary hypertension (PH) community are preparing to participate in PHenomenal Hope 5K, an event established to raise disease awareness and research funds for Team PHenomenal Hope. Held this year on April 27, the flat-course event will begin and…

Patients with pulmonary hypertension (PH) living in the U.K. experience delayed diagnosis, which has important implications for their financial and emotional status, according to a survey conducted by the Pulmonary Hypertension Association UK (PHA-UK). The results were described in an article, titled…

Myth 1: If you can’t run with the big dogs, stay on the porch.  Truth: In the words of the late great Dr. Martin Luther King Jr., “if you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you…

The health regulatory agency for Australia has approved Mallinckrodt Pharmaceuticals‘ INOmax (nitric oxide) gas for inhalation as a treatment for adult patients with perioperative pulmonary hypertension (PH) in combination with cardiovascular (heart) surgery. INOmax is a vasodilator inhalation device that works by widening and relaxing blood vessels…

United Therapeutics announced it has ended its Phase 3 BEAT trial testing esuberaprost as an add-on therapy to its product Tyvaso (inhaled treprostinil) for clinically symptomatic patients with pulmonary arterial hypertension (PAH). According to a company press release, the study failed to reach its main endpoint of delaying the…

The U.S. Food and Drug Administration (FDA) has agreed to change the ongoing Phase 2b study  evaluating INOpulse in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) into a Phase 2/3 clinical trial, the therapy’s manufacturer, Bellerophon Therapeutics, announced. With this decision the agency also agreed to change the…

Combined therapy with Revatio (sildenafil) and Opsumit (macitentan) was effective in a patient diagnosed with pulmonary hypertension (PH) associated with a rare blood disorder called polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, a case report shows. The…

Increased levels of a protein called LRP1 may lead to blood vessel remodeling in pulmonary hypertension (PH) by causing changes in pulmonary artery cells that favor their proliferation, a study suggests. The study, “LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension,”…

Systemic hypertension is an independent predictor in rare cases of pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE), a retrospective large-cohort study in Taiwan shows. According to the findings, most of the observed PAH cases occurred within five years of SLE diagnosis. The study, “Incidence and…